PE20231203A1 - Anticuerpos de cadena pesada que se unen al receptor de folato alfa - Google Patents

Anticuerpos de cadena pesada que se unen al receptor de folato alfa

Info

Publication number
PE20231203A1
PE20231203A1 PE2023001680A PE2023001680A PE20231203A1 PE 20231203 A1 PE20231203 A1 PE 20231203A1 PE 2023001680 A PE2023001680 A PE 2023001680A PE 2023001680 A PE2023001680 A PE 2023001680A PE 20231203 A1 PE20231203 A1 PE 20231203A1
Authority
PE
Peru
Prior art keywords
cancer
heavy chain
receptor alpha
folate receptor
bind
Prior art date
Application number
PE2023001680A
Other languages
English (en)
Spanish (es)
Inventor
Katherine Harris
Brian Avanzino
Nathan Trinklein
Hannes Kehm
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20231203A1 publication Critical patent/PE20231203A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2023001680A 2020-11-18 2021-11-17 Anticuerpos de cadena pesada que se unen al receptor de folato alfa PE20231203A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18
PCT/US2021/059701 WO2022109010A1 (en) 2020-11-18 2021-11-17 Heavy chain antibodies binding to folate receptor alpha

Publications (1)

Publication Number Publication Date
PE20231203A1 true PE20231203A1 (es) 2023-08-17

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001680A PE20231203A1 (es) 2020-11-18 2021-11-17 Anticuerpos de cadena pesada que se unen al receptor de folato alfa

Country Status (18)

Country Link
US (1) US20240002498A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247498A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549851A (cg-RX-API-DMAC7.html)
KR (1) KR20230110303A (cg-RX-API-DMAC7.html)
CN (1) CN116615253A (cg-RX-API-DMAC7.html)
AR (1) AR124084A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021383743A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199785A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001432A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006790A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230259A (cg-RX-API-DMAC7.html)
IL (1) IL302670A (cg-RX-API-DMAC7.html)
JO (1) JOP20230109A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005693A (cg-RX-API-DMAC7.html)
PE (1) PE20231203A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233684A (cg-RX-API-DMAC7.html)
UY (1) UY39522A (cg-RX-API-DMAC7.html)
WO (1) WO2022109010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
EP4577576A4 (en) * 2022-08-22 2026-08-12 Abdera Therapeutics Inc KIDNEY-TARGETING ANTIBODIES
TW202608930A (zh) * 2024-06-05 2026-03-01 大陸商長春金賽藥業有限責任公司 靶向葉酸受體α(FRα)的抗體、雙特異性抗體和偶聯物,及其製備和用途
WO2026133379A1 (en) * 2024-12-20 2026-06-25 Fondazione Irccs Istituto Nazionale Dei Tumori Bispecific antibodies directed against alpha-folate receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3765521A4 (en) * 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
CA3133654A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma

Also Published As

Publication number Publication date
TW202233684A (zh) 2022-09-01
US20240002498A1 (en) 2024-01-04
CL2025003126A1 (es) 2026-01-23
EP4247498A1 (en) 2023-09-27
AU2021383743A1 (en) 2023-06-08
IL302670A (en) 2023-07-01
CO2023006790A2 (es) 2023-06-09
CR20230259A (es) 2023-07-13
AU2021383743A9 (en) 2024-09-26
CN116615253A (zh) 2023-08-18
WO2022109010A1 (en) 2022-05-27
UY39522A (es) 2022-06-30
KR20230110303A (ko) 2023-07-21
CL2023001432A1 (es) 2024-01-05
CA3199785A1 (en) 2022-05-27
MX2023005693A (es) 2023-05-29
AR124084A1 (es) 2023-02-08
JP2023549851A (ja) 2023-11-29
JOP20230109A1 (ar) 2023-05-18

Similar Documents

Publication Publication Date Title
PE20190737A1 (es) Anticuerpos anti-cd27
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CO2018004094A2 (es) Polipéptidos de unión a cd3
PE20221262A1 (es) Anticuerpos terapeuticos y sus usos
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
GEAP201914392A (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20180795A1 (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
MX2017002230A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
EA202092302A1 (ru) Антитела к trem-1 и их применения
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
EA202090401A1 (ru) Анти-tim-3 антитела и их применение